INSILICO Aktie

 

Find insight on Insilico, CSL, Sonic Healthcare and more in the latest Market Talks covering health care....

CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to......

Hong Kong Exchanges and Clearing (HKEX) will add 10 companies – including autonomous-driving firms Pony AI and WeRide – to its Tech 100 Index as part of a quarterly reshuffle that increases the benchmark's exposure to artificial intelligence and other emerging technologies. Other additions include AI drug-discovery specialist Insilico Medicine, printed-circuit-board maker Victory Giant Technology, enterprise AI company Beijing Haizhi Technology and AI data-intelligence provider Mininglamp......

HKEX (00388.HK) announced the results of the September quarterly review of the HKEX Tech 100 Index. The quarterly adjustment adopted the optimized compilation methodology announced earlier this month.The Tech 100 Index will add WERIDE-W (00800.HK), PONY-W (02026.HK), VGT (02476.HK), HAIZHI TECH GP (02706.HK), MININGLAMP-W (02718......

Alex Zhavoronkov, Founder & CEO at Insilico Medicine, discusses the AI-drug discovery firm's earnings and business outlook exclusively on "Bloomberg: The China Show." (Source: Bloomberg)...

CAMBRIDGE, Mass., Aug. 26, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the Company achieved total revenue of US$106.......

INSILICO (03696.HK) announced its interim results for the six months ended June 2026. Revenue amounted to USD106 million, up 287.2% YoY. The company swung to a profit of USD35.54 million, compared with a loss of USD19.22 million in the corresponding period last year. EPS was USD0.06. No dividend was declared.During the period, a......

CAMBRIDGE, Mass., Aug. 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in MSCI Global Small Cap Indexes compiled by Morgan Stanley Capital......

Following a decade of exploration from the 2014 NVIDIA GTC to the PreciousGPT model series, Insilico Medicine presents the industry's first multi-agent Virtual Aging Cell (VAC) platform with biological age as a core condition. CAMBRIDGE, Mass., Aug. 14, 2026 /PRNewswire/ -- Insilico......

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small......

CAMBRIDGE, Mass., Aug. 11, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that it will hold conference calls to discuss its financial results for the six months ended......

As a dual-purpose, potential first-in-class, "pipeline-in-a-drug" candidate, ISM9077 provides an innovative solution for ocular diseases, inflammatory disorders, and the fundamental aging process. ISM9077 was designed, evaluated and optimized utilizing Chemistry42's integrated generative......

The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict disease before it begins. SAN FRANCISCO, Aug. 3,......

INSILICO (03696.HK) announced that its self-developed pan-TEAD inhibitor ISM6331 has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable malignant pleural mesothelioma whose disease has progressed following prior anti-PD-1 antibody therapy (with o......

Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

JPMorgan published a research report initiating coverage on two Chinese AI-aided drug discovery (AIDD) companies, INSILICO (03696.HK) and XTALPI (02228.HK), both with Overweight ratings.JPMorgan said China's AIDD industry is transitioning from the commercial exploration stage to early commercialization, driven by increasing ......

HSBC Global Investment Research issued a report initiating coverage on INSILICO (03696.HK) with a Buy rating and a target price of HKD84.5.The report stated that INSILICO is transitioning from a concept stock to commercialization through partnerships with leading pharmaceutical companies. Its commercial execution has demonstrate......

AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class, brain-penetrant, non-opioid solution for pain management. Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated......

TENCENT (00700.HK)'s Tencent Health announced a strategic partnership with INSILICO (03696.HK). The two parties will integrate the full chain from underlying computing power and large-model foundations to biomolecular reasoning, aiming to accelerate innovative drug R&D and drive digital efficiency improvements in the pha......